10/10: The Bottom Line
$GIL is currently a battleground stock. It’s a classic "show me" story—management must prove their operational integrity through cold, hard cash flow data.
Are you buying the dip, or is this a signal to stay away? Let me know below. 👇
1/10: Is $GIL a value play or a house of cards?
Short-seller Jehoshaphat Research just fired a major shot at $GIL, alleging "channel stuffing"—forcing products onto distributors to artificially inflate sales.
The bull vs. bear case. 🧵
https://t.co/liIntLhXEM?
9/10: The Blue Sky PathFor $GIL to fly, we need a "clean" earnings report in the next two quarters showing:
Significant inventory clearance success.
Re-acceleration of organic sales.
Rapid debt paydown using free cash flow.If they nail this, the valuation re-rates higher.
12/12: The core thesis is simple: $JRSH has the capacity, the demand, and the balance sheet to scale. Now, it's all about execution. Are you watching the manufacturing sector, or are you staying on the sidelines with $JRSH? Let me know below. 👇
1/12: $JRSH is shifting from a "recovery play" to a "growth engine." After a record-breaking FY2026, the market is finally getting the signal it needed: the narrative is moving from surviving regional instability to aggressive capacity expansion. 🧵
11/12: The Blue Sky scenario? $JRSH exceeds the high target if they announce a major new partnership with a global brand in the next 6 months, proving that their capacity expansion isn't just about current clients, but capturing significant new market share.